People: Adverum Biotechnologies Inc (ADVM.OQ)
7 Aug 2020
Dr. Laurent Fischer M.D. serves as Chief Executive Officer, Director of the Company. He served as Senior Vice President, Head of the Liver Therapeutic Area at Allergan, a global pharmaceutical company, from November 2016 until June 2020, in which position he was responsible for the development of Allergan’s NASH pipeline. Prior to Allergan, Dr. Fischer served as Chief Executive Officer of Tobira Therapeutics, a clinical-stage biopharmaceutical company, from 2013 until Allergan acquired Tobira Therapeutics in November 2016, in which position he was responsible for overseeing all aspects of the company. Dr. Fischer has served as a Senior Advisor on the Life Sciences Team of Frazier Healthcare Partners, a venture capital company, since March 2017. Prior to Tobira, he served as Chairman and Chief Executive Officer of Jennerex, Inc., until its acquisition by SillaJen Biotherapeutics, Inc. Prior to Jennerex, he was co-founder, President and Chief Executive Officer of Ocera Therapeutics and President and Chief Executive Officer of Auxeris Therapeutics, Inc. Over the span of his career, Dr. Fischer has held roles of increasing responsibility at several other companies, including, RXCentric, Inc. (now part of Allscripts Healthcare Solutions, Inc.), MedVantx Inc., Dupont Pharmaceuticals, Dupont-Merck, and F. Hoffmann-La Roche.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|